Monopar Therapeutics MNPR

$ 22.0 -7.74%

Quarterly report 2024-Q3
added 11-08-2024

Monopar Therapeutics Balance Sheet 2011-2025 | MNPR

Annual Balance Sheet Monopar Therapeutics

	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Net Debt	-8.18 M	-	-16.7 M	-13.2 M	-6.89 M	-8.98 M	-2.07 M	-	-	-	-	-
Long Term Debt	-	8.41 K	-	-	-	-	-	-	-	-	-	-	-
Long Term Debt Current	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Current Liabilities	1.76 M	3.13 M	1.58 M	1.18 M	724 K	400 K	312 K	-	-	-	-	-	-
Total Liabilities	1.76 M	3.14 M	1.58 M	1.18 M	724 K	400 K	312 K	64.5 K	-	-	-	-	-
Deferred Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-
Retained Earnings	-60.2 M	-51.8 M	-41.3 M	-32.2 M	-25.9 M	-21.7 M	-18.4 M	-1.87 M	-	-	-	-	-
Total Assets	7.35 M	13.2 M	20.5 M	16.9 M	13.4 M	7.32 M	9.93 M	2.9 M	-	-	-	-	-
Cash and Cash Equivalents	7.27 M	8.19 M	20.3 M	16.7 M	13.2 M	6.89 M	8.98 M	2.87 M	-	-	-	-	-
Book Value	5.59 M	10.1 M	18.9 M	15.7 M	12.6 M	6.92 M	9.62 M	2.83 M	-	-	-	-	-
Total Shareholders Equity	5.59 M	10.1 M	18.9 M	15.7 M	12.6 M	6.92 M	9.62 M	2.83 M	-	-	-	-	-

All numbers in USD currency

Quarterly Balance Sheet Monopar Therapeutics

	2024-Q3	2024-Q2	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
Long Term Debt	-	-	-	-	-	-	8.41 K	20.8 K	33.1 K	25.3 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	54.6 K	75 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Liabilities	1.12 M	1.09 M	1.76 M	1.98 M	2.5 M	2.89 M	3.14 M	1.94 M	2.22 M	1.1 M	1.58 M	1.24 M	1.1 M	-	1.18 M	1.18 M	1.18 M	444 K	724 K	724 K	724 K	724 K	400 K	400 K	400 K	400 K	312 K	312 K	312 K	312 K	64.5 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Retained Earnings	-64.9 M	-63.6 M	-60.2 M	-58.4 M	-56.4 M	-54.2 M	-51.8 M	-48.9 M	-46.5 M	-43.7 M	-41.3 M	-38.6 M	-36.1 M	-34.1 M	-32.2 M	-32.2 M	-32.2 M	-32.2 M	-25.9 M	-25.9 M	-25.9 M	-25.9 M	-21.7 M	-21.7 M	-2.4 K	-21.7 M	-18.4 M	-18.4 M	-18.4 M	-18.4 M	-1.87 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Assets	6.07 M	7.18 M	7.35 M	8.59 M	10.3 M	11.8 M	13.2 M	14.4 M	16.7 M	18.1 M	20.5 M	22.5 M	24.5 M	25.9 M	16.9 M	16.9 M	16.9 M	16.9 M	13.4 M	13.4 M	13.4 M	13.4 M	7.32 M	7.32 M	7.32 M	7.32 M	9.93 M	9.93 M	9.93 M	9.93 M	2.9 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cash and Cash Equivalents	6.02 M	6.12 M	7.27 M	5.52 M	7.21 M	5.73 M	8.19 M	14.3 M	16.5 M	17.8 M	20.3 M	22.3 M	24.3 M	25.7 M	16.7 M	16.7 M	16.7 M	16.7 M	13.2 M	13.2 M	13.2 M	13.2 M	6.89 M	6.89 M	6.89 M	6.89 M	8.98 M	8.98 M	8.98 M	8.98 M	2.07 M	-	-	-	2.81 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Book Value	4.95 M	6.09 M	5.59 M	6.61 M	7.84 M	8.94 M	10.1 M	12.5 M	14.5 M	17 M	18.9 M	21.3 M	23.4 M	25.9 M	15.7 M	15.7 M	15.7 M	16.4 M	12.6 M	12.6 M	12.6 M	12.6 M	6.92 M	6.92 M	6.92 M	6.92 M	9.62 M	9.62 M	9.62 M	9.62 M	2.83 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Shareholders Equity	4.95 M	6.09 M	5.59 M	6.61 M	7.84 M	8.94 M	10.1 M	12.5 M	14.5 M	17 M	18.9 M	21.3 M	23.4 M	25.1 M	15.7 M	15.7 M	15.7 M	15.7 M	12.6 M	12.6 M	12.6 M	12.6 M	6.92 M	6.92 M	6.92 M	6.92 M	9.62 M	9.62 M	9.62 M	9.62 M	2.83 M	-	-	-	2.75 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency